Skip to main content
Premium Trial:

Request an Annual Quote

It Turns Out They Didn't Want to Give Up Their Kidneys

Derek Lowe has a post at his In the Pipeline blog looking at SGX Pharmaceuticals' foray into phase I trials with a therapeutic that emerged from X-ray crystallographic screening. "Here's a good example of why all of us in the industry tiptoe into Phase I trials, the first-in-man studies," Lowe writes. SGX, now owned by Lilly, took a promising kinase inhibitor into clinical trials last year -- and pulled it just two months later after finding that "higher doses were associated with acute renal failure, something that most certainly hadn't been noticed in the mouse models, or the rats, or the dogs," Lowe says, noting that until that point the drug appeared to be "a perfectly reasonable-looking drug candidate."

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.